Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Singapore
Singapore: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage was 91.0% in 2024. ▲ Rising
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Singapore, 2009–2024
Source: WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data. Measured in %.
Analysis
In 2024, pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Singapore stood at 91.0%.
Compared with earlier readings it is down 2.2% on the previous year and up 33.8% over ten years.
Over the whole period, pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Singapore peaked at 93.0% in 2023 and was at its lowest, 17.0%, in 2009.
Singapore ranks 52nd of 146 countries on this measure, in the middle of the range.
The long-run direction has been consistently rising across the 16 years of available data.
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Singapore, year by year
| Year | % | Change |
|---|---|---|
| 2009 | 17.0% | — |
| 2010 | 22.0% | +29.4% |
| 2011 | 40.0% | +81.8% |
| 2012 | 52.0% | +30.0% |
| 2013 | 60.0% | +15.4% |
| 2014 | 68.0% | +13.3% |
| 2015 | 75.0% | +10.3% |
| 2016 | 78.0% | +4.0% |
| 2017 | 83.0% | +6.4% |
| 2018 | 84.0% | +1.2% |
| 2019 | 84.0% | +0.0% |
| 2020 | 87.0% | +3.6% |
| 2021 | 88.0% | +1.1% |
| 2022 | 90.0% | +2.3% |
| 2023 | 93.0% | +3.3% |
| 2024 | 91.0% | -2.2% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 17.0% | 17.0% | 17.0% | 1 |
| 2010s | 64.6% | 22.0% | 84.0% | 10 |
| 2020s | 89.8% | 87.0% | 93.0% | 5 |
Countries ranked near Singapore
More health data for Singapore
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5225 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,924 deaths per 1,000 people (2090)
- Number of infants who die before age 1 13 deaths (2100)
- Population ages 0-14, female, annual growth rate 1.32 % change on previous year (2025)
- Population ages 0-14, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, female, per capita 0.0571 units per person (2025)
- Population ages 0-14, male, annual growth rate 1.19 % change on previous year (2025)
- Population ages 0-14, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, male, per capita 0.0598 units per person (2025)
Frequently asked questions
- What is pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Singapore?
- Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Singapore was 91.0% in 2024, according to WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data.
- What is the highest pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage recorded in Singapore?
- The highest recorded value was 93.0% in 2023.
- What is the lowest pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage recorded in Singapore?
- The lowest recorded value was 17.0% in 2009.
- How does Singapore rank for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Singapore ranks 52nd out of 146 countries with data for 2024.
- Is pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage rising or falling in Singapore?
- Over the last ten years it is up 33.8%. The long-run trend across the full record is rising.
- Where does this Singapore data come from?
- The figures come from WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as part of Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 16 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.